Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biophytis Reinforces Leadership Teams with Three Senior Appointments
BIOPHYTIS SAJuly 8, 2021 GMT
Claude Allary to be member of Board of Directors
Benoit Canolle is appointed Chief Business Officer Jean Mariani, Chairman of Biophytis Scientific Committee to take over the Chief Medical Officer role
PARIS and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the strengthening of its leadership teams with three new appointments of highly experienced healthcare
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos .
BIOPHYTIS SAMay 12, 2021 GMT This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data
The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays
PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, t
Share:
nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data
The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays
PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ( BIOPHYTIS or the Company ), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it has recruited the 155th participant for Part 2 of its COVA Phase 2-3 study of Sarconeos (BIO101) in patients infected with COVID-19.
Message :
Required fields
PARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting.
BIOPHYTIS’ combined AGM took place today behind closed doors, due to the COVID-19 pandemic.